Disease Domain | Count |
---|---|
Neoplasms | 10 |
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Proteolysis-targeting chimeras (PROTAC) | 1 |
Unknown | 1 |
Antibody fusion proteins | 1 |
Therapeutic vaccine | 1 |
Target |
Mechanism NPRA agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SIRT6 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HDAC6 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Start Date15 Feb 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Recombinant human Atrial Natriuretic Peptide(Chinese Academy of Medical Sciences) ( NPRA ) | Heart Failure More | Phase 3 |
Laxiflorin B-4 ( ERK1 x ERK2 ) | Non-Small Cell Lung Cancer More | Preclinical |
Z16b ( RYR2 ) | Tachycardia, Ventricular More | Preclinical |
2-APQC ( SIRT3 ) | Cardiomegaly More | Preclinical |
compound 8 (Shenzhen University ) ( GSK-3β x QPCT ) | Alzheimer Disease More | Preclinical |